UPEXI INC
For the period ended Jun 30, 2024. Filed Dec 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 16, 2024
UPXI$0.66+3.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
UPEXI, INC.
CONSOLIDATED BALANCE SHEETS
| June 30, | June 30, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash | $661,415 | $4,492,292 |
| Accounts receivable, net | 606,885 | 1,125,394 |
| Inventory, net | 1,431,556 | 4,804,299 |
| Due from Bloomios | - | 845,443 |
| Due from VitaMedica transition | 212,358 | - |
| Prepaid expenses and other receivables | 502,188 | 1,112,280 |
| Assets available for sale - Interactive offers current | - | 89,989 |
| Assets available for sale - Building | 4,005,516 | 4,611,248 |
| Assets available for sale - VitaMedica current | - | 2,599,934 |
| Assets available for sale - E-core current | - | 10,332,105 |
| Purchase price receivable - VitaMedica | 2,000,000 | - |
| Purchase price receivable - E-core | 2,000,000 | - |
| Total current assets | 11,419,918 | 30,012,984 |
| Property and equipment, net | 2,356,556 | 2,831,375 |
| Intangible assets, net | 239,871 | 6,924,982 |
| Goodwill | 848,854 | 2,886,309 |
| Deferred tax asset | 5,948,858 | 5,604,056 |
| Other assets | 278,435 | 76,728 |
| Discontinued assets available for sale - Interactive offers | - | 936,054 |
| Discontinued assets available for sale - VitaMedica | - | 2,051,214 |
| Discontinued assets available for sale - E-core | - | 12,067,333 |
| Right-of-use asset, net | 2,418,596 | 410,453 |
| Total other assets | 12,091,170 | 33,788,504 |
| Total assets | $23,511,088 | $63,801,488 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $481,647 | $1,028,611 |
| Accrued compensation | 1,098,856 | 533,842 |
| Deferred revenue | 235,255 | - |
| Accrued liabilities | 736,407 | 2,439,794 |
| Accrued interest | 476,018 | 655,187 |
| Acquisition payable | 413,152 | 152,500 |
| Related party advances, net | 100,000 | - |
| Current portion of note payable | - | 338,474 |
| Current portion of convertible notes payable | - | 1,254,167 |
| Current portion of acquisition note payable - E-core | - | 5,656,620 |
| Current portion of related party note payable | - | 1,429,356 |
| Current portion of Cygnet subsidiary notes payable | 5,447,565 | 795,778 |
| Note payable on building for sale | 2,634,538 | 2,841,566 |
| Discontinued liabilities - Interactive offers | - | 792,408 |
| Discontinued liabilities - VitaMedica | - | 617,174 |
| Discontinued liabilities - E-core | - | 3,401,983 |
| Current portion of operating lease payable | 1,031,714 | 454,127 |
| Total current liabilities | 12,655,152 | 22,391,587 |
| Operating lease payable, net of current portion | 1,732,606 | - |
| Related party note payable | 500,000 | - |
| Note payable | 557,429 | 173,812 |
| Convertible notes payable | 1,550,000 | 895,833 |
| Acquisition note payable - E-core | - | 7,605,085 |
| Notes payable - Cygnet subsidiary | - | 4,898,548 |
| Total long-term liabilities | 4,340,035 | 13,573,278 |
| Commitments and contingencies | ||
| Stockholders' equity | ||
| Preferred stock, $0.001 par value, 500,000 shares authorized, and 25,000 and 25,000 shares issued and outstanding, respectively | 25 | 25 |
| Common stock, $0.001 par value, 5,000,000 shares authorized, and 1,010,843 and 1,045,429 shares issued and outstanding, respectively | 1,045 | 1,011 |
| Additional paid in capital | 53,374,444 | 51,541,909 |
| Accumulated deficit | (46,859,613) | (23,201,175) |
| Total stockholders' equity attributable to Upexi, Inc. | 6,515,901 | 28,341,770 |
| Non-controlling interest in subsidiary | (505,147) | |
| Total stockholders' equity | 6,515,901 | 27,836,623 |
| Total liabilities and stockholders' equity | $23,511,088 | $63,801,488 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.